台灣臨床試驗主持人資料庫|TPIDB

問卷

問卷調查提醒

您好：邀請您填寫網站的問卷意見調查表，讓我們有更多優化及改進的方向，一起提升使用者體驗。

系統通知

此案目前為暫存狀態

編修至YYYY/MM/DD

不開放編輯功能

確認送出

我同意

請先勾選「我同意」

當您勾選「我同意」時，表示您已閱讀、了解並同意接受本「會員同意書及隱私權政策」內容

繁中 EN

TPIDB

TPIDB Outstanding PI Advanced Search 聯絡我們

繁中 EN

TPIDB Outstanding PI

TPIDB > Study Site

Study Site

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Link to Hospital │ Link to Clinical Trial Center

726

Total Beds
258

Total Doctors

IMS@w.tmu.edu.tw
International Medical Center
886-2 29307930*7766/7767/7768
116Taipei CityWun ShanWanFang Hospital 1st Floor (No.111, Sec. 3, Xinglong Rd., Wenshan Dist., Taipei City 116, Taiwan)

Recruiting Trial

74Cases

Site Introduction Principal Investigator List Clinical Trials List

請選擇要匯出的欄位

全選

Plan Title (TW)

Plan Title (EN)

Plan No

NCT No

Start Date

End Date

Trial Phase

ICD-9

ICD-10

Applicant

CRO (TW)

CRO (EN)

Trial Scale

Indication (TW)

Indication (EN)

Purpose (TW)

Purpose (EN)

Drug Name (TW)

Drug Name (EN)

ATC Code

Ingredient (TW)

Ingredient (EN)

Dose Type (TW)

Dose Type (EN)

Dose (TW)

Dose (EN)

Evaluation (TW)

Evaluation (EN)

Inclusions (TW)

Inclusions (EN)

Exclusions (TW)

Exclusions (EN)

Taiwan Quantity

Global Quantity

IIT

Hospital

Accept Qty

Contact Name (TW)

Contact Name (EN)

Contact Phone (TW)

Contact Phone (EN)

Contact Email (TW)

Contact Email (EN)

Co-PI

Modify Search

Find Division/Department

All Location

All Division/Department

All Division/Department
Division of Internal Medicine
Division of Surgery
Division of Others

篩選

Developmental Phase

Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others

Trial Status

Not yet recruiting
Active
Completed

Recruitment Status

Not yet recruiting
Recruiting
Completed
Terminated
Stop recruiting
Suspended
Study ended

Trial scale

Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center

The expected start time interval of the test

Trial Applicant

Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization

Important Roles

Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None

Audit by Sponsors/CRO

Sponsors
CRO
None

Investigator-initiated trial(IIT)

Filters

List

196Cases

2013-11-01 - 2016-06-20

Phase III

A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate and Intravenous to Oral 10-Day Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Condition/Disease

Acute Bacterial Skin and SkinStructure Infections
Test Drug

Tedizolid Phosphate

Participate Sites
7Sites

Study ended7Sites

2009-07-01 - 2013-08-31

Phase III

Condition/Disease
Test Drug

Participate Sites
12Sites

Terminated12Sites

2015-06-30 - 2017-12-31

Phase IV

A post marketing surveillance study of Lipo-AB® (amphotericin B) in neutropenic patients with persistent fever

Condition/Disease

neutropenic
Test Drug

amphotericin B

Participate Sites
10Sites

Terminated9Sites

李文生

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Infectious Disease

2015-05-01 - 2017-03-25

Phase III

A randomized, double-blind, active drug-controlled, parallel grouping trial, in patients with severe to very severe chronic obstructive pulmonary disease (COPD), using tiotropium as a benchmark to evaluate oral inhaled tiotropium + olodaterol fixed-dose combination once a day The effect of 52-week treatment on the acute onset of COPD. [DYNAGITO]

Condition/Disease

COPD
Test Drug

Tiotropium + Olodaterol fixed dose combination (FDC) inhalation solution- RESPIMATR Inhaler

Participate Sites
15Sites

Terminated13Sites

鍾飲文

Kaohsiung Municipal Gangshan Hospital

未分科

鍾啟禮

Taipei Medical University Hospital

Division of Thoracic Medicine

2008-12-01 - 2011-07-31

Phase III

Condition/Disease
Test Drug

Participate Sites
14Sites

Terminated14Sites

2010-09-01 - 2012-07-01

Phase III

A phase III randomized, double-blind, placebo-controlled, parallel trial to evaluate BI 10773 (10 mg, 25 mg) orally once a day for a 24 week course of treatment after treatment with Metformin or combined Metformin and Sulfonylurea Efficacy and safety of type 2 diabetes patients with poor blood glucose control

Condition/Disease

Type 2 or unspecified diabetes
Test Drug

BI 10773

Participate Sites
9Sites

Terminated9Sites

2011-05-01 - 2013-06-30

Phase III

A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (incl. 24 weeks of preceding trial) as monotherapy or with different back-ground therapies in patients with type 2 diabetes mellitus previously completing trial 1245.19, 1245,20 or 1245.23.

Condition/Disease

Type 2 diabetes
Test Drug

BI 10773

Participate Sites
9Sites

Terminated9Sites

2017-08-01 - 2020-04-30

Phase III

A multinational, multi-center, randomized, double-blind, active comparator, phase III clinical trial to evaluate the efficacy and safety of donepezil transdermal patch in patients with Alzheimer’s disease

Condition/Disease

mild to moderate Alzheimer's disease patient
Test Drug

Donepezil transdermal patch

Participate Sites
12Sites

Terminated12Sites

楊淵韓

Kaohsiung Municipal Ta-Tung Hospital

Division of Neurology

2017-07-01 - 2018-09-30

Phase II

A Phase 2, Double-blind, Randomized Controlled Study to Evaluate Immunogenicity and Safety of Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult Volunteers

Condition/Disease

Influenza Virus Vaccine
Test Drug

AD07030

Participate Sites
5Sites

Terminated5Sites

劉明哲

Taipei Medical University Hospital

Division of Urology

李文生

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Infectious Disease

2021-06-01 - 2023-12-31

Phase II

Condition/Disease
Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 Previous page 16 17 18 19 20

搜尋計畫列表下載細項

全部

試驗主持人
實際收案人數

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB